ADAG

Adagene Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Current Price

—

Profile

Valuation (TTM)

Market Cap—

P/E—

EV—

P/B—

Shares Out—

P/Sales—

Revenue—

EV/EBITDA—

Adagene Inc (ADAG) Quality Analysis

ADAG GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

ADAG Profitability

Profitability trend analysis coming soon

ADAG Growth

Growth trend analysis coming soon

ADAG Financial Health

Financial health indicators coming soon

ADAG Quality & Fundamental Analysis

Adagene Inc (ADAG) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Adagene Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Adagene Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency..

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Adagene Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.